Potential utility of recombinant human GM-CSF as adjunctive treatment of refractory oropharyngeal candidiasis in AIDS patients

Eur J Clin Microbiol Infect Dis. 1998 Nov;17(11):781-3. doi: 10.1007/s100960050185.

Abstract

The aim of the study was to investigate the use of granulocyte macrophage-colony stimulating factor (GM-CSF) as an adjunctive treatment for clinically refractory mucosal candidiasis in patients with advanced AIDS. Three patients with advanced AIDS and oropharyngeal candidiasis clinically refractory to azoles or amphotericin B received GM-CSF for 14 days along with either fluconazole or amphotericin B. All three patients showed clinical improvement and mycological improvement without any adverse events. Thus, GM-CSF may be a possible alternative as adjunctive therapy in the management of refractory mucosal candidiasis in patients with advanced AIDS.

Publication types

  • Case Reports
  • Clinical Trial

MeSH terms

  • AIDS-Related Opportunistic Infections / drug therapy*
  • Anti-HIV Agents / therapeutic use
  • Antifungal Agents / administration & dosage
  • Antifungal Agents / pharmacology
  • Antifungal Agents / therapeutic use
  • Candida / drug effects
  • Candida / isolation & purification
  • Candida albicans / drug effects
  • Candida albicans / isolation & purification
  • Candidiasis, Oral / drug therapy*
  • Drug Therapy, Combination
  • Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use*
  • Humans
  • Microbial Sensitivity Tests
  • Oropharynx / microbiology
  • Pilot Projects
  • Recombinant Proteins

Substances

  • Anti-HIV Agents
  • Antifungal Agents
  • Recombinant Proteins
  • Granulocyte-Macrophage Colony-Stimulating Factor